South Africa Pulmonary Arterial Hypertension Market Outlook

pulmonary arterial hypertension (pah) is a life-threatening disorder in which the arteries that transport blood from the heart to the lungs become narrowed, reducing the amount of oxygen reaching the body. the prevalence of pah in south africa is estimated to be high as it is a relatively undiagnosed disease, but due to the significant unmet medical need that exists, the south african government has implemented a variety of measures to ensure that pah patients have access to appropriate treatment and care. the south african pah market is expected to experience significant growth over the forecast period (2018 to 2032) as the government continues to implement favorable initiatives such as the payment of premium for initiation and continuation of treatment with oral medications used used to treat pah. furthermore, the government has strengthened regulatory infrastructure by introducing legislation which requires that all physicians working in specialized areas of cardiology, pulmonology and nephrology be adequately qualified in the diagnosis and treatment of pah, thus further facilitating the uptake of novel and improved pah therapies. additionally, a number of biopharmaceutical companies have increased their focus on south africa due to the large and diverse population and the availability of a highly-skilled medical workforce. furthermore, the south african pah patient population is expected to benefit from the introduction of biotherapeutics such as martinacalcet, which is a novel oral drug used to treat secondary hyperparathyroidism due to advanced chronic kidney disease in patients with limited or no access to conventional injectable treatment. another promising therapeutic candidate for the south african market is cogentol, a drug used to treat pah that has been approved in the european union and the united states. in conclusion, the south african pah market is expected to experience considerable growth over the forecast period (2018 to 2032) due to the implementation of favorable government initiatives, increasing presence of biopharmaceutical companies and the availability of numerous innovative therapies. moreover, as the south african pah patient population continues to rise, it is likely that more treatments will become available in the next decade, further driving the growth of the pah market in south africa.